COMPRESSED MATTER: WHY YOUNGER & FASTER MEANS BIGGER

COMPRESSED MATTER: WHY YOUNGER & FASTER MEANS BIGGER

While the US population is 500% bigger than the UK’s, size alone does not account for the discrepancy in economic success of the top 5 stocks listed in the US and the UK. Selecting a sector where it is possible to create highly exponential rates of growth, so-called hyperscaling, is perhaps an even more important factor.

While the US population is 500% bigger than the UK’s, size alone does not account for the discrepancy in economic success of the top 5 stocks listed in the US and the UK. Selecting a sector where it is possible to create highly exponential rates of growth, so-called hyperscaling, is perhaps an even more important factor.

This is why the five biggest US stocks by market cap are more than 12x larger than the UK’s but one fifth of the average age (the average age of the UK’s top five is c 150 years versus 32 years in the US). Also, the average market cap of the US top five is US$1.4tn, while no single company listed in the UK is worth more than a tenth of that.

Company Market cap (US$tn) Age Market cap (US$tn) Age
Apple Inc 2.02 45 Unilever 0.14 92
Microsoft Corp 1.71 46 AstraZeneca 0.12 108
Amazon.com Inc 1.5 27 HSBC 0.14 136
Alphabet Inc 1.38 23 Rio Tinto 0.1 148
Facebook Inc 0.73 17 Diageo 0.1 272
Total 7.34 158 0.58 756
Average 1.47 31.6 0.12 151

Source: Thomson Reuters at 5 March 2021. Note: *Ages based on the oldest direct ancestor of present legal entity.

To quote Lord Hill’s report of last week, ‘the most significant companies listed in London are either financial or more representative of the ‘old economy’ than the companies of the future.’

What does this mean? Could the UK change its trajectory? If so, how? We would very much like to hear your thoughts on our Twitter and LinkedIn feeds. Our analysts will be joining the discussion as well.

Latest

news

Supercharge your IR with AI coaching

news

Forbes: Andy Murphy in Forbes

news

CNBC: Neil Shah on Squawk Box

Seven things every investor should know about SIGA technologies & biological weapons

Nasdaq-listed SIGA Technologies (SIGA) is a profitable pharmaceuticals business, focused on safeguarding against viruses as biological weapons. We value SIGA, an Edison client, at US$968m or $12.61/ per share.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free